Actively Recruiting
Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer
Led by Quanda Liu · Updated on 2026-03-06
30
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
Sponsors
Q
Quanda Liu
Lead Sponsor
L
Liaoning Cancer Hospital & Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, multicenter, randomized, and open-label clinical trial. It is initiated to determine the efficacy of FOLFOX-based, transarterial infusion chemotherapy (TAIC) combined with either cetuximab or bevacizumab for patients with unresectable colorectal cancer (CRC).
CONDITIONS
Official Title
Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Colorectal cancer confirmed by CT, MRI, and colonoscopic biopsy
- Patients unfit for surgery due to poor general condition or tumor extent and location
- Patients who have not received prior chemotherapy or who have undergone prior chemotherapy but remain chemosensitive
- Adequate blood, heart, liver, and kidney functions as specified (e.g., white blood cell count ≥4000/mL, neutrophils ≥1500/mm³, platelets ≥100×10⁹/L, hemoglobin ≥10.0 g/L, total bilirubin ≤2.0 mg/dL, liver enzymes ≤100 IU/L, serum creatinine ≤1.5 mg/dL or creatinine clearance ≥60 mL/min/body, urine protein/creatinine <1)
- Expected life expectancy of at least 3 months
- Signed informed consent form
You will not qualify if you...
- Presence of other primary malignant tumors
- Gastrointestinal perforation
- Allergy to antitumor agents
- Women who are pregnant, breastfeeding, or planning to become pregnant
- Concurrent use of other antitumor treatments such as chemotherapy, targeted therapy, or radiotherapy
- Microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) colorectal cancer
- Participation deemed inappropriate by the doctor or investigator for any other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Xicheng, Beijing Municipality, China, 100053
Actively Recruiting
Research Team
Q
Quanda Liu Chief physician, MD
CONTACT
J
Junpeng Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here